Literature DB >> 2935528

Activation of plasminogen by pro-urokinase. I. Mechanism.

H R Lijnen, C Zamarron, M Blaber, M E Winkler, D Collen.   

Abstract

The mechanism of the activation of plasminogen by recombinant pro-urokinase (Rec-pro-UK), obtained by expression of the human pro-urokinase gene in Escherichia coli, was investigated in purified systems. In mixtures of Rec-pro-UK and plasminogen, both active urokinase and plasmin are quickly generated. Addition of plasmin inhibitors (aprotinin or alpha 2-antiplasmin) abolishes the conversion of Rec-pro-UK to urokinase but not the activation of plasminogen to plasmin, suggesting that Rec-pro-UK activates plasminogen directly. Human plasma competitively inhibits the activation of plasminogen by pro-urokinase with a Ki of 0.2% (v/v). This explains the relative stability of Rec-pro-UK in plasma and the lack of activation of the plasma fibrinolytic system in the absence of fibrin. The competitive inhibition by plasma is abolished by the addition of CNBr-digested fibrinogen although Rec-pro-UK has no specific affinity for fibrin. These findings suggest that the fibrin specificity of the activation of plasminogen by pro-urokinase is due to neutralization by fibrin of the competitive inhibition exerted by plasma and not to fibrin-enhanced activation of plasminogen.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2935528

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Immunohistological detection of Saruplase (recombinant single-chain urokinase-type plasminogen activator) in normal rat tissue.

Authors:  T Wöhrmann; T Matthiesen; H Beier; L Flohé
Journal:  Histochemistry       Date:  1991

2.  Human endothelial cell line, ECV304, produces pro-urokinase.

Authors:  K Takahashi; Y Sawasaki
Journal:  In Vitro Cell Dev Biol       Date:  1991-10

Review 3.  Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.

Authors:  R Fears
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

4.  Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.

Authors:  R Pannell; J Black; V Gurewich
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

5.  Urokinase-type plasminogen activator (uPA) regulates the expression and function of growth-associated protein 43 (GAP-43) in the synapse.

Authors:  Paola Merino; Ariel Diaz; Enrique R Torre; Manuel Yepes
Journal:  J Biol Chem       Date:  2019-12-09       Impact factor: 5.157

Review 6.  Physiology and pathophysiology of the plasminogen system in the kidney.

Authors:  Per Svenningsen; Gitte Rye Hinrichs; Rikke Zachar; Rikke Ydegaard; Boye L Jensen
Journal:  Pflugers Arch       Date:  2017-06-27       Impact factor: 3.657

Review 7.  Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.

Authors:  J Nazari; R Davison; K Kaplan; D Fintel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

8.  Expression of full-length human pro-urokinase in mammary glands of transgenic mice.

Authors:  Yaroslav Gursky; Robert Bibilashvili; Mikchail Minashkin; Alex Krasnov; Alex Deikin; Tatyana Ermolkevich; Andrey Popov; Lilia Verbovaya; Nicolai Rutkevich; Alexsander Shevelev; Sofia Georgieva; Sergey V Razin; Igor Goldman; Elena Sadchikova
Journal:  Transgenic Res       Date:  2009-04-25       Impact factor: 2.788

Review 9.  New strategies in the development of thrombolytic agents.

Authors:  H R Lijnen; D Collen
Journal:  Blut       Date:  1988-10

Review 10.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.